LATEST NEWS | 6th Jun 2022 Anteris 9 News Interview

Investor Centre

Investor News

Visit the news page to see the latest news.

Why Invest?

The FDA approval of Transcatheter Aortic Valve Replacement (TAVR) in the treatment of low-risk (younger patients) is driving rapid market expansion. Today we have

The Right Opportunity
to introduce a potential functional cure in the treatment of Aortic Stenosis where hemodynamics are reverted to normal pre-disease status and sustained for the life of the patient.

With TAVR now being the treatment of choice for Aortic Stenosis patients, coupled with existing Transcatheter Heart Valves failing as early as five to eight years after implantation, then now is

The Right Time
for a solution that Works Better & Lasts Longer.

At Anteris we bring

The Right Technology
to patients requiring a replacement valve. DurAVR™ heart valves address both the acute need in terms of superior hemodynamic profile, as well as chronic needs in their ability to sustain that profile longer, over the lifetime of the patient.

The inspiration for our DurAVR™ heart valves* stemmed from multiple conversations with interventional cardiologists, who reiterated that valve durability and repeat replacements were posing a large risk to patient health.

The proven benefits of our ADAPT® tissue paired with the unique design of DurAVR™ our 3D single-piece aortic valve, answers the need to

potentially deliver a functional cure
in the treatment of Aortic Stenosis, and provides a much-needed solution to the challenges facing heart surgeons today.

Learn more about
The Right Technology
, visit now ,

At Anteris we are committed in delivering durable solutions through our Better Science & Better Design that help healthcare professionals create life-changing outcomes for patients.

ASX Announcements

Showing - of
⚑ = Price Sensitive
Subscribe to the ASX Annoucements Feed

Financial Reports

  • 2021 Annual Report
  • 2021 Consolidated Half Year Financial Report
  • 2020 Annual Report
  • 2020 Consolidated Half Year Financial Report
  • 2019 Annual Report
  • 2019 Consolidated Half Year Financial Report
  • 2018 Annual Report
  • 2018 Consolidated Half Year Financial Report
  • 2017 Annual Report (Jul 17 - Dec 17)
  • 2017 Annual Report (Jul 16 - Jun 17)
  • 2017 Consolidated Half Year Financial Report (Jul 16 - Dec 16)
  • 2016 Annual Report
  • 2016 Consolidated Half Year Financial Report
  • 2015 Annual Report
  • 2015 Consolidated Half Year Financial Report

Research Reports

  • AVR Desk Note - Whairo Capital - Jan 2022
  • Bioshares November 2020 Report
  • Bioshares July 2020 Report
  • Bioshares June 2020 Report

Annual General Meetings

Share Registry

Computershare Investor Services Pty Ltd

Level 1, 200 Mary Street
Brisbane, QLD 4000

T 1300 850 505 (within Australia)
T +61 3 9415 4000 (outside Australia)
F 1800 783 447 (within Australia)
F +61 3 9473 2555 (outside Australia)

ComputerShare Investor Services manages our share registry. You can contact them for details about your holding here.

A copy of our recent top 20 shareholder list is available here.

Holders of Unlisted Options

Conversion Notice and Payment
If you hold unlisted options and wish to exercise those options to convert them into ordinary shares of Anteris Technologies Ltd, you will need to complete an exercise form and submit payment within the period prior to expiry, please contact us at and we will be able to provide you with the exercise form which includes details of how to submit payment.

If you have any questions in relation to any of the above, please contact Computershare Investor Services Pty Limited on +61 1300 850 505 or the Company on +61 1300 550 310 or

Contact Us